- Inicio
- Listar por autor
Listar por autor "Garrido-Navas, M. Carmen"
Mostrando ítems 1-3 de 3
-
Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
Simon, Iris; Perales, Sonia; Casado-Medina, Laura; Rodríguez-Martínez, Alba; Garrido-Navas, M. Carmen ; Puche-Sanz, Ignacio; Diaz-Mochon, Juan J.; Alaminos, Clara; Lupiañez, Pablo; Lorente, José Antonio; Serrano, M. José; Real, Pedro J. (Cancers, 2021)Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) are the goal standard for metastatic prostate cancer (PCa) treatment. Although ADT is initially effective, a subsequent ... -
Telomere Instability in Lynch Syndrome Families Leads to Some Shorter Telomeres in MSH2+/- Carriers
Garrido-Navas, M. Carmen ; Tippins, Frances; Barwel, Julian; Hoffman, Jonathan; Codd, Veryan; Royle, Nicola J. (Life-Basel, 11/2020)Lynch syndrome (LS) is an inherited predisposition to early onset of various cancers, caused by mutation in a DNA mismatch repair (MMR) gene. In heterozygous MMR+/- carriers, somatic mutation, loss or silencing of the wild ... -
The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers
Garrido-Navas, M. Carmen ; García-Díaz, Abel; Molina-Vallejo, María Pilar; González-Martínez, Coral; Alcaide Lucena, Miriam; Cañas-García, Inés; Bayarri, Clara; Delgado, Juan Ramón; González, Encarna; Lorente, José Antonio; Serrano, M. José (Cancers, 11/2020)Being minimally invasive and thus allowing repeated measures over time, liquid biopsies are taking over traditional solid biopsies in certain circumstances such as those for unreachable tumors, very early stages or treatment ...